- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotoxins for leukemia
Authors
Keywords
-
Journal
BLOOD
Volume 123, Issue 16, Pages 2470-2477
Publisher
American Society of Hematology
Online
2014-02-28
DOI
10.1182/blood-2014-01-492256
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- GM-CSF-DFF40: a novel humanized immunotoxin induces apoptosis in acute myeloid leukemia cells
- (2013) Mrudula Mathew et al. APOPTOSIS
- Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy
- (2013) Y.-T. Hsieh et al. BLOOD
- Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells
- (2013) Sonja Schiffer et al. CANCER LETTERS
- Antibody–drug conjugates for the treatment of B-cell non-Hodgkin’s lymphoma and leukemia
- (2013) Yu-Waye Chu et al. Future Oncology
- A Modified Form of Diphthamide Causes Immunotoxin Resistance in a Lymphoma Cell Line with a Deletion of theWDR85Gene
- (2013) Hui Wei et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Adipose tissue attracts and protects acute lymphoblastic leukemia cells from chemotherapy
- (2013) Rocky Pramanik et al. LEUKEMIA RESEARCH
- Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8
- (2013) Xiaobo Hu et al. LEUKEMIA RESEARCH
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hairy Cell Leukemia—New Genes, New Targets
- (2013) Robert J. Kreitman Current Hematologic Malignancy Reports
- Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
- (2012) W. Haso et al. BLOOD
- Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia
- (2012) Tadeusz Robak Future Oncology
- Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies
- (2012) G. Borthakur et al. HAEMATOLOGICA
- Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
- (2012) Robert J. Kreitman et al. JOURNAL OF CLINICAL ONCOLOGY
- Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia
- (2012) Stefan K. Barta et al. LEUKEMIA & LYMPHOMA
- Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia
- (2012) Jason Kato et al. LEUKEMIA RESEARCH
- Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity
- (2012) Xiao-yun Liu et al. mAbs
- Targeting malignant B cells with an immunotoxin against ROR1
- (2012) Sivasubramanian Baskar et al. mAbs
- My Treatment Approach to Hairy Cell Leukemia
- (2012) Rahul R. Naik et al. MAYO CLINIC PROCEEDINGS
- Restricted Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Pediatric B-Lineage Acute Lymphoblastic Leukemia Suggests Targetability with Therapeutic Monoclonal Antibodies
- (2012) Hema Dave et al. PLoS One
- Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes
- (2012) W. Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy
- (2012) H. Wei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia
- (2011) John Schindler et al. BRITISH JOURNAL OF HAEMATOLOGY
- Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates
- (2011) D. J. FitzGerald et al. CANCER RESEARCH
- Synergistic Antitumor Activity of Anti-CD25 Recombinant Immunotoxin LMB-2 with Chemotherapy
- (2011) R. Singh et al. CLINICAL CANCER RESEARCH
- Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
- (2011) R. J. Kreitman et al. CLINICAL CANCER RESEARCH
- Genome-Wide RNAi Screens Identify Genes Required for Ricin and PE Intoxications
- (2011) Dimitri Moreau et al. DEVELOPMENTAL CELL
- The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC- II depletion
- (2011) V. Biberacher et al. HAEMATOLOGICA
- Cancer radioimmunotherapy
- (2011) Robert M Sharkey et al. Immunotherapy
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
- (2011) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- 3A4, a new potential target for B and myeloid lineage leukemias
- (2011) Sisi Li et al. JOURNAL OF DRUG TARGETING
- Immunotoxins with decreased immunogenicity and improved activity
- (2011) Ira Pastan et al. LEUKEMIA & LYMPHOMA
- Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737
- (2011) David J. Fitzgerald et al. LEUKEMIA & LYMPHOMA
- The improvement of an anti-CD22 immunotoxin
- (2011) Seiji Kawa et al. mAbs
- Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes
- (2011) M. Onda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia
- (2010) Francis Mussai et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Flow Cytometry Method to Quantitate Internalized Immunotoxins Shows that Taxol Synergistically Increases Cellular Immunotoxins Uptake
- (2010) Y. Zhang et al. CANCER RESEARCH
- Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial
- (2010) A. S. Wayne et al. CLINICAL CANCER RESEARCH
- Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity
- (2010) Thomas R. Malek et al. IMMUNITY
- In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA′ in a human acute myeloid leukemia xenograft tumor model
- (2010) Mehmet Kemal Tur et al. INTERNATIONAL JOURNAL OF CANCER
- Modified DT–IL2 fusion toxin targeting uniquely IL2Rα expressing leukemia cell lines – Construction and characterization
- (2010) Sirisha Potala et al. JOURNAL OF BIOTECHNOLOGY
- Antibody-targeted horseradish peroxidase associated with indole-3-acetic acid induces apoptosis in vitro in hematological malignancies
- (2010) Leandro F.F. Dalmazzo et al. LEUKEMIA RESEARCH
- “Inclonals”
- (2010) Rahely Hakim et al. mAbs
- ATG-saporin-S6 immunotoxin: a new potent and selective drug to eliminate activated lymphocytes and lymphoma cells
- (2009) Letizia Polito et al. BRITISH JOURNAL OF HAEMATOLOGY
- Anti-CD3 Recombinant Diphtheria Immunotoxin Therapy of Cutaneous T Cell Lymphoma
- (2009) A. Frankel et al. CURRENT DRUG TARGETS
- Denileukin diftitox: a novel immunotoxin
- (2009) George Manoukian et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia
- (2009) Robert J. Kreitman et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase 1 Study of Combotox in Pediatric Patients With Refractory B-lineage Acute Lymphoblastic Leukemia
- (2009) Larry Herrera et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability
- (2009) B ten Cate et al. LEUKEMIA
- Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy
- (2009) Daniel A. Vallera et al. LEUKEMIA RESEARCH
- A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity
- (2008) J. E. Weldon et al. BLOOD
- Differential Cellular Internalization of Anti-CD19 and -CD22 Immunotoxins Results in Different Cytotoxic Activity
- (2008) X. Du et al. CANCER RESEARCH
- An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes
- (2008) M. Onda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now